https://synptide.com/research What changed in peptide, GLP-1, and longevity evidence — new trials, regulatory actions, and every Synptide evidence-grade change. https://synptide.com/research/updates/compound-directory-launch Editorial We published canonical, outcome-graded profiles for the first 25 compounds, plus a public A–U evidence framework and this change log. Sat, 11 Jul 2026 00:00:00 GMT https://synptide.com/research/updates/compound-directory-launch https://synptide.com/research/updates/semaglutide-select-cardiovascular Evidence-grade change We set semaglutide's cardiovascular-outcome grade to A after the SELECT trial's 20% reduction in major cardiovascular events in people with obesity but without diabetes. Wed, 08 Jul 2026 00:00:00 GMT https://synptide.com/research/updates/semaglutide-select-cardiovascular https://synptide.com/research/updates/tirzepatide-osa-approval Label change We added obstructive sleep apnea as an A-graded, FDA-approved indication for tirzepatide following the SURMOUNT-OSA trials. Sat, 20 Jun 2026 00:00:00 GMT https://synptide.com/research/updates/tirzepatide-osa-approval https://synptide.com/research/updates/bpc-157-compounding-status Regulatory We clarified BPC-157's status after the FDA placed it in the category that restricts compounding-pharmacy use, reinforcing its research-chemical grade. Fri, 15 May 2026 00:00:00 GMT https://synptide.com/research/updates/bpc-157-compounding-status